MX384875B - Método para obtener una vacuna de mycoplasma. - Google Patents

Método para obtener una vacuna de mycoplasma.

Info

Publication number
MX384875B
MX384875B MX2018014818A MX2018014818A MX384875B MX 384875 B MX384875 B MX 384875B MX 2018014818 A MX2018014818 A MX 2018014818A MX 2018014818 A MX2018014818 A MX 2018014818A MX 384875 B MX384875 B MX 384875B
Authority
MX
Mexico
Prior art keywords
obtaining
subject
immunogenic composition
mycoplasma
relates
Prior art date
Application number
MX2018014818A
Other languages
English (en)
Inventor
Arun V Iyer
Axel Neubauer
Brian Thomas Martinson
Christine Margaret Muehlenthaler
Dianna M Murphy Jordan
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384875(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX384875B publication Critical patent/MX384875B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere, entre otros, a un método para la preparación de una composición inmunogénica para el tratamiento y/o la profilaxis de infecciones por micoplasmas en un sujeto, que comprende cultivar bacterias de Mycoplasma en un sistema de células eucarióticas con una cantidad reducida de suero o libre de suero porcino; obtener un antígeno de las bacterias de Mycoplasma; y agregar un portador farmacéuticamente aceptable. Además, la presente invención se refiere a la composición inmunogénica que se puede obtener mediante dicho método y a un método para inmunizar a un sujeto, que comprende la administración de la composición inmunogénica a un sujeto.
MX2018014818A 2012-12-28 2013-12-20 Método para obtener una vacuna de mycoplasma. MX384875B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746997P 2012-12-28 2012-12-28
PCT/US2013/076807 WO2014105672A1 (en) 2012-12-28 2013-12-20 Method of making a mycoplasma vaccine

Publications (1)

Publication Number Publication Date
MX384875B true MX384875B (es) 2025-03-14

Family

ID=49917778

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014818A MX384875B (es) 2012-12-28 2013-12-20 Método para obtener una vacuna de mycoplasma.
MX2015007730A MX361273B (es) 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007730A MX361273B (es) 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma.

Country Status (23)

Country Link
US (2) US9273281B2 (es)
EP (1) EP2938747B1 (es)
JP (2) JP6122146B2 (es)
KR (1) KR102153275B1 (es)
CN (2) CN108379571A (es)
AR (1) AR094648A1 (es)
AU (1) AU2013370983B2 (es)
BR (1) BR112015012711B1 (es)
CA (1) CA2896298C (es)
CL (1) CL2015001562A1 (es)
DK (1) DK2938747T3 (es)
EA (1) EA032772B1 (es)
ES (1) ES2738100T3 (es)
HU (1) HUE045015T2 (es)
MX (2) MX384875B (es)
MY (1) MY173223A (es)
PH (1) PH12015501333B1 (es)
PL (1) PL2938747T3 (es)
PT (1) PT2938747T (es)
SG (2) SG10201708028VA (es)
TW (2) TWI660736B (es)
UA (1) UA121193C2 (es)
WO (1) WO2014105672A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
DK2938747T3 (da) 2012-12-28 2019-08-05 Boehringer Ingelheim Vetmedica Gmbh Fremgangsmåde til fremstilling af en mycoplasma vaccine
UA121097C2 (uk) * 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
EP3408281A4 (en) * 2016-01-29 2019-08-14 Advanced Animal Diagnostics, Inc. METHOD AND COMPOSITIONS FOR DETECTING MYCOPLASMA EXPOSURE
CN109310113A (zh) 2016-03-22 2019-02-05 先进动物诊断股份有限公司 减少农场动物抗生素施用的方法和组合物
KR102251603B1 (ko) * 2016-08-09 2021-05-14 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 마이코플라즈마 하이오라이니스 감염의 예방 및 치료용 조성물 및 조성물의 생산 방법
WO2018144909A1 (en) * 2017-02-03 2018-08-09 The Administrators Of The Tulane Educational Fund Ophthalmic compositions for therapeutic and prophylactic uses
EP3632982A1 (en) 2017-05-24 2020-04-08 Mitsubishi Chemical Corporation Molding material and fiber-reinforced composite material
WO2020251847A1 (en) 2019-06-10 2020-12-17 Elanco Us Inc. Mycoplasma media formulations
CN113201050B (zh) * 2020-08-06 2022-07-22 青岛诺安百特生物技术有限公司 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
GB1074920A (en) * 1965-04-21 1967-07-05 Pfizer & Co C Growth medium for mycoplasma pneumoniae and vaccine production
ES343655A1 (es) 1966-07-11 1968-09-01 Research Corp Metodo para la preparacion de un inoculo para aves de co- rral.
JPS5540568B2 (es) 1972-10-05 1980-10-18
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
EP1260581B1 (en) * 2000-03-03 2010-07-07 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3402304B2 (ja) * 2000-03-30 2003-05-06 株式会社微生物化学研究所 猫クラミジアワクチンの製造方法
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
PT1474067E (pt) 2001-07-02 2008-11-14 Pfizer Prod Inc Vacinação numa dose com mycoplasma hyopneumoniae
WO2003004051A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
HUP0401077A3 (en) 2001-08-28 2004-10-28 Pfizer Prod Inc Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
CA2595556A1 (en) 2005-02-09 2006-08-17 Magna International Inc. Method of manufacturing a semi-structural panel
JP4693839B2 (ja) 2005-03-10 2011-06-01 共立製薬株式会社 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法
WO2007042827A2 (en) * 2005-10-14 2007-04-19 Ivan Petyaev Treatment and diagnosis of obligate intracellular pathogens
KR101464783B1 (ko) 2006-09-15 2014-11-26 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CN104043116A (zh) * 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
JP5613061B2 (ja) 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
JPWO2009142086A1 (ja) 2008-05-23 2011-09-29 学校法人 久留米大学 マイコプラズマ感染症用ワクチン組成物
WO2009156960A2 (en) 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
BRPI1010679B1 (pt) 2009-05-19 2020-09-24 Bioproperties Pty Ltd Cepa de vacina de mycoplasma hyopneumoniae sensível à temperatura e aplicações da mesma, composiçao de vacina, método de preparaçao e uso da mesma
US20110150770A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
US8112663B2 (en) 2010-03-26 2012-02-07 Lsi Corporation Method to establish redundancy and fault tolerance better than RAID level 6 without using parity
CN102258776B (zh) 2011-07-07 2013-07-10 普莱柯生物工程股份有限公司 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
DK2938747T3 (da) * 2012-12-28 2019-08-05 Boehringer Ingelheim Vetmedica Gmbh Fremgangsmåde til fremstilling af en mycoplasma vaccine
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм

Also Published As

Publication number Publication date
SG11201505089YA (en) 2015-07-30
HUE045015T2 (hu) 2019-11-28
AU2013370983A1 (en) 2015-05-21
AR094648A1 (es) 2015-08-19
PL2938747T3 (pl) 2019-11-29
ES2738100T3 (es) 2020-01-20
EA201500701A1 (ru) 2015-12-30
UA121193C2 (uk) 2020-04-27
US20160136254A1 (en) 2016-05-19
SG10201708028VA (en) 2017-10-30
US20140186394A1 (en) 2014-07-03
PT2938747T (pt) 2019-08-01
PH12015501333A1 (en) 2015-09-02
KR20150100920A (ko) 2015-09-02
PH12015501333B1 (en) 2022-10-05
JP6449364B2 (ja) 2019-01-09
WO2014105672A1 (en) 2014-07-03
CL2015001562A1 (es) 2016-06-24
TW201438732A (zh) 2014-10-16
BR112015012711A2 (pt) 2017-07-11
CA2896298C (en) 2024-01-16
AU2013370983B2 (en) 2019-09-26
BR112015012711B1 (pt) 2022-08-16
US10512680B2 (en) 2019-12-24
EP2938747A1 (en) 2015-11-04
KR102153275B1 (ko) 2020-09-09
US9273281B2 (en) 2016-03-01
EA032772B1 (ru) 2019-07-31
TW201832777A (zh) 2018-09-16
DK2938747T3 (da) 2019-08-05
CN104968365B (zh) 2018-04-03
EP2938747B1 (en) 2019-05-01
CN108379571A (zh) 2018-08-10
MX2015007730A (es) 2015-09-07
JP2017145253A (ja) 2017-08-24
JP2016508983A (ja) 2016-03-24
MY173223A (en) 2020-01-07
JP6122146B2 (ja) 2017-04-26
CA2896298A1 (en) 2014-07-03
TWI660736B (zh) 2019-06-01
MX361273B (es) 2018-12-03
TWI618542B (zh) 2018-03-21
CN104968365A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
MY173223A (en) Method of making a mycoplasma vaccine
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201792407A2 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
IN2013MU00711A (es)
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX382924B (es) Composición para prevenir infección por mycoplasma spp.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
EA201491845A1 (ru) Получение стерильных активных фармацевтических ингредиентов
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
MX363044B (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
IN2011CH03893A (es)
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
IN2013CH04314A (es)
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
AR093687A2 (es) Vacunas
IN2013MU01944A (es)